Disabled
Macroautophagy
mTOR — the master growth switch — stays on chronically in aging, suppressing the cellular cleanup that health requires. Rapamycin is the most replicated lifespan drug in mammals. The question is how to deliver the same signal without side effects.
The Mechanism
The growth-vs-cleanup switch — and why it gets stuck
mTORC1 (mechanistic Target of Rapamycin Complex 1) integrates nutrient abundance signals — amino acids (via Rag GTPases), glucose (via PI3K/Akt), and growth factors (via Rheb) — and, when active, drives protein synthesis while blocking autophagy via ULK1 phosphorylation. AMPK does the opposite: activated by low energy (high AMP/ATP ratio), it suppresses mTOR and activates ULK1, turning on cellular recycling.
Aging creates permanent mTOR bias: insulin resistance (elevated insulin even when fasted) keeps mTORC1 basally active. Reduced AMPK activity (from mitochondrial inefficiency and NAD+ decline) removes the counter-signal. The result is cells that never fully enter the cleanup state — accumulating damaged proteins, dysfunctional organelles, and lipid droplets.
The therapeutic insight from rapamycin research: it is never too lateto suppress mTOR and extend healthspan. Harrison et al. (Nature 2009) started rapamycin in mice at 20 months (equivalent to ~60 human years) and extended median lifespan 9–14%. This suggests mTOR inhibition acts on reversible aging processes, not just developmental ones.
Non-pharmaceutical mTOR suppression stack: fasting windows(suppress via amino acid depletion), resveratrol (AMPK/SIRT1), NMN (sirtuin counterbalance to mTOR), and low refined carbohydrate diet (insulin/IGF-1 reduction). Combined, these approximate ~40% of rapamycin’s mTOR inhibition without immunosuppressive risk.
Monitoring
Nutrient sensing biomarkers
Evidence-Graded Interventions
mTOR suppression — from lifestyle to clinical
Tier A = multiple human RCTs. Tier B = at least one human trial + mechanistic data. Listed from most to least accessible.
Caloric Restriction / Strategic Fasting
Tier AThe most replicated lifespan intervention across species. CR suppresses mTORC1 (via reduced amino acid and glucose signaling through Rag GTPases and DEPTOR), activates AMPK (via rising AMP/ATP), and derepresses autophagy, SIRT1/3, and mitophagy simultaneously. The CALERIE human trial (PMID: 27544442) confirmed favorable metabolic and inflammatory changes at 2 years.
Resveratrol → AMPK / Sirtuin Axis
Tier BResveratrol activates AMPK directly (via LKB1 pathway) and SIRT1 allosterically — both upstream activators of autophagy and mitochondrial biogenesis. AMPK phosphorylates ULK1 (autophagy initiation) and TFEB (lysosome biogenesis). SIRT1 deacetylates PGC-1α, driving mitochondrial renewal. Acts as a CR-mimetic compound.
NMN → SIRT1 / mTOR Counterbalance
Tier BSirtuins (SIRT1, SIRT3, SIRT6) counterbalance mTOR signaling: SIRT1 suppresses mTORC1 via TSC2 deacetylation; SIRT6 deacetylates H3K9 to suppress ribosomal gene expression (the downstream target of mTOR). As NAD+ falls with age, this sirtuin brake on mTOR is lost — restoring NAD+ via NMN reactivates it.
Rapamycin (mTOR Inhibitor)
Tier BRapamycin is the most replicated life-extending drug across species — extending median lifespan 9–14% in aged mice even when started late (Harrison et al., Nature 2009, PMID: 19587683). It allosterically inhibits mTORC1, inducing autophagy, senescent cell clearance, and immune rejuvenation. Immunosuppressive risks at daily dosing are largely avoided with weekly administration.
Metformin (AMPK Activator)
Tier BMetformin inhibits mitochondrial Complex I, raising the AMP/ATP ratio and activating AMPK — mimicking caloric restriction at the molecular level. It also suppresses hepatic gluconeogenesis and mTOR. The TAME (Targeting Aging with Metformin) trial is the first FDA-endorsed aging intervention trial, expected to complete ~2027.
Flip the switch back to cleanup mode.
Fasting + resveratrol + NMN is the OTC rapamycin-mimic stack. Build it, track fasting insulin, and watch mTOR tone normalize.